Abstract 13043: Atrial Fibrillation is Associated With Cardiovascular Events in Obese Japanese With One or More Cardiovascular Risk Factors: Japan Morning Surge Home Blood Pressure (J-HOP) Study
Introduction: Obesity has been shown as a risk of incidence and durability of atrial fibrillation. However, the relationship between obesity and prognosis of patients with atrial fibrillation remains unclear.
Hypothesis: We assessed the hypothesis that obesity was associated with cardiovascular events in atrial fibrillation patients with cardiovascular risk factors.
Methods: We enrolled 3,585 patients in the Japan Morning Surge Home Blood Pressure Study who had one or more cardiovascular risk factors. We conducted 12-lead electrocardiography, and atrial fibrillation was identified based on electrocardiography. Obesity was defined as body mass index over than 25 kg/m2. The primary endpoints were fatal/nonfatal cardiovascular events (myocardial infarction, stroke, hospitalization for heart failure, aortic dissection).
Results: The number of patients whose electrocardiograms revealed atrial fibrillation was eighty-four. In obese patients, atrial fibrillation patients (N=35) suffered more cardiovascular events (log rank 7.17, p=0.007) than sinus rhythm patients (N=1282), but in nonobese patients, cardiovascular events were similar (log rank 0.10, p=0.76) in atrial fibrillation (N=48) and sinus rhythm patients (N=2220). After adjusting for age, gender, hypertension, smoking, and diabetes, atrial fibrillation was an independent predictor of cardiovascular events in the obese group (hazard ratio 3.02, 95% confidence interval 1.18-7.78).
Conclusions: There was a significant difference in the association between atrial fibrillation and subsequent cardiovascular events in the presence or absence of obesity. Weight reduction might improve the prognosis of atrial fibrillation patients.
Author Disclosures: H. Watanabe: None. T. Kabutoya: Honoraria; Modest; Medtronic Japan Co., Ltd., Daiichi Sankyo, Co. Ltd., Bayer Yakuhin Ltd., Meiji Seika Pharma Co., Ltd.. S. Hoshide: None. K. Kario: Research Grant; Significant; Teijin Pharma Limited, Novartis Pharma K.K., Takeda Pharmaceutical Co., Ltd., OMRON HEALTHCARE Co., Ltd., FUKUDA DENSHI. Honoraria; Modest; Mitsubishi Tanabe Pharma Corporation., Kyowa Hakko Kirin Co., Ltd., Bayer Yakuhin Ltd., Pfizer Japan Inc., Shionogi & Co., Ltd., Astellas Pharma Inc., AstraZeneca K.K., Boehringer Ingelheim Japan Inc., Sanofi K.K., GlaxoSmithKline K.K., TERUMO Corporation., Bristol-Myers K.K., Kowa Pharmaceutical Co. Ltd., Medtronic Japan Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Roche Diagnostics K.K., MSD K.K.. Honoraria; Significant; Mochida Pharmaceutical Co.,Ltd., Takeda Pharmaceutical Co.,Ltd., Daiichi Sankyo Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd..
- © 2015 by American Heart Association, Inc.